Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 12/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.48 |
| ▸ | SYK | P43405 | 2/20 | 0.45 |
| ▸ | ACACB | O00763 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | IDH2 | P48735 | 2/20 | 0.39 |
| ▸ | POLQ | O75417 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3827250 | 1.00 | HRH4 (0.51) | HRH4HRH3SYKACACBMCHR1 | |
| SCHEMBL4499542 | 0.92 | IDH2 (0.43) | HRH4HRH3SYKACACBIDH2 | |
| SCHEMBL4476424 | 0.88 | HRH3 (0.58) | HRH4HRH3SYKACACBPOLQ | |
| SCHEMBL30475275 | 0.81 | KDM4E (0.50) | ACACBPOLQ | |
| SCHEMBL30475250 | 0.79 | NOTUM (0.55) | ACACBIDH2 | |
| SCHEMBL10169427 | 0.78 | HRH3 (0.55) | HRH4HRH3 | |
| SCHEMBL30475258 | 0.77 | CRHBP (0.51) | HRH4ACACB | |
| SCHEMBL1352123 | 0.76 | ADRB1 (0.57) | HRH4HRH3SYKACACBIDH2 | |
| SCHEMBL1352121 | 0.76 | ADRB1 (0.57) | HRH4HRH3SYKACACBIDH2 | |
| SCHEMBL5086363 | 0.76 | ADRB1 (0.57) | HRH4HRH3SYKACACBIDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1603899-B1 | HETEROCYCLIC UREA DERIVATIVES FOR THE TREATMENT OF PAIN | GLAXO GROUP LTD (GB) | 2009-08-26 | — | — | EP | disclosed |
| US-7528151-B2 | Heterocyclic urea derivatives for the treatment of pain | GLAXO GROUP LIMITED (GB) | 2009-05-05 | — | — | US | disclosed |
| US-20070117820-A1 | Heterocyclic urea derivatives for the treatment of pain | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-05-24 | — | — | US | disclosed |
| WO-2004024710-A1 | UREA COMPOUNDS ACTIVE AS VANILLOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | GLAXO GROUP LIMITED (GB) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117820-A1 | Heterocyclic urea derivatives for the treatment of pain | U2SURP, UMPS, SFPQ | HRH4 92/4885HRH3 234/4885SYK 3087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.